Int. J. Curr. Res. Med. Sci. (2026). 12(3): 32-42

International Journal of Current Research in Medical Sciences

ISSN: 3107-3743 (Print), ISSN: 2454-5716 (Online)
(A Peer Reviewed, Indexed and Open Access Journal)
www.ijcrims.com

Review Article

Volume 12, Issue 3 -2026

DOI: http://dx.doi.org/10.22192/ijcrms.2026.12.03.004

Hemostatic Dysregulation in Anemic Children: Bridging the Gap Between Oxygen Transport and Coagulation Function

***Emmanuel Ifeanyi Obeagu[1],[2] and Ohiwerei Wisdom Omogbai[3]**

[1]Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

[2]Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health 3Sciences, University of the Witwatersrand, Johannesburg, South Africa Department of Medical and Laboratory Science, Mudiame University, Irua, Edo State, Nigeria.

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, , ORCID: 0000-0002-4538-0161 *emmanuelobeagu@yahoo.com*

Abstract

Anemia in children is a prevalent condition worldwide, often resulting in impaired oxygen delivery to tissues and organs. Beyond its classical effects, anemia influences the delicate balance of the hemostatic system, leading to a spectrum of coagulation abnormalities. This review explores the complex interactions between oxygen transport deficits and hemostatic dysregulation in pediatric anemia, highlighting how hypoxia-driven mechanisms contribute to altered platelet function and coagulation factor expression. The pathophysiological mechanisms underlying hemostatic disturbances in anemic children involve hypoxia-induced endothelial activation, modulation of platelet reactivity, and variations in coagulation protein levels. These changes create a paradoxical environment where children are simultaneously at risk for bleeding and thrombotic complications, depending on the anemia type and severity. Clinical conditions such as sickle cell disease exemplify this dual risk, underscoring the need for comprehensive hemostatic evaluation in affected pediatric populations.

Keywords: : Pediatric anemia, Hemostasis, Coagulation dysfunction, Oxygen transport, Hypoxia.

Introduction

Anemia is a pervasive global health problem, particularly in pediatric populations, affecting millions of children worldwide. Defined by a reduction in hemoglobin concentration or red blood cell mass, anemia leads to impaired oxygen transport and tissue hypoxia, which can have profound consequences on growth, development, and overall health [1-2]. In children, anemia arises from diverse etiologies including nutritional deficiencies (such as iron, folate, or vitamin B12), inherited hemoglobinopathies, chronic infections, and bone marrow disorders. While the clinical manifestations of anemia primarily revolve around fatigue, pallor, and developmental delays, its influence extends to the regulation of hemostasis, a relationship that is often underrecognized but clinically significant [3-4].Hemostasis is a tightly regulated physiological process that maintains blood fluidity while preventing excessive bleeding through a balance between procoagulant and anticoagulant forces. The coagulation cascade, platelet function, and endothelial integrity work in concert to preserve vascular integrity after injury. Disruptions in this balance can result in bleeding tendencies or thrombotic events. In the context of anemia, this equilibrium is perturbed due to the complex interactions between impaired oxygen delivery and alterations in vascular and hematological function. Pediatric patients with anemia thus represent a unique subset in whom hemostatic dysregulation warrants careful evaluation [5-6].

The connection between oxygen transport and hemostatic function is mediated largely by tissue oxygenation status. Hypoxia, a consequence of anemia, acts as a biological stressor that triggers endothelial cell activation, inflammation, and oxidative stress. These changes alter the expression of key molecules such as tissue factor, thrombomodulin, and nitric oxide, all of which influence coagulation pathways. Moreover, hypoxia-inducible factors (HIFs) regulate genes involved in both erythropoiesis and coagulation, linking oxygen sensing mechanisms directly with hemostatic control. This pathophysiological crosstalk is particularly relevant in pediatric anemia, where chronic hypoxia may exacerbate hemostatic imbalance [7-8].Platelets, the cellular mediators of primary hemostasis, are also affected by anemia-induced hypoxia. Evidence suggests that hypoxic conditions enhance platelet adhesion and aggregation, increasing thrombotic potential in some cases. Conversely, certain forms of anemia are associated with thrombocytopenia or qualitative platelet defects due to marrow suppression or nutrient deficiencies. This dual effect complicates clinical prediction of bleeding or clotting risks in anemic children and underscores the need for individualized assessment [9-11].

Coagulation factor abnormalities further compound the hemostatic challenges in anemic children. Iron deficiency anemia, for example, is linked to decreased levels of von Willebrand factor and factor VIII, predisposing patients to mucocutaneous bleeding. In contrast, hemolytic anemias such as sickle cell disease are characterized by chronic inflammation and endothelial dysfunction that promote a hypercoagulable state. These divergent effects illustrate how different anemia etiologies can variably influence coagulation factor synthesis and activity, highlighting the heterogeneity of hemostatic dysfunction in this population [12-13].Clinically, hemostatic dysregulation in anemic children manifests as an increased risk for both hemorrhagic and thrombotic complications, which can contribute significantly to morbidity and mortality [14-15]. For instance, children with sickle cell anemia have heightened risks of stroke and vaso-occlusive crises linked to hypercoagulability, while those with iron deficiency may experience excessive bleeding during surgical procedures or trauma. Despite this, routine coagulation testing often fails to capture subtle hemostatic abnormalities related to anemia. This diagnostic gap emphasizes the importance of integrating hemostatic assessment with anemia evaluation for comprehensive clinical care [16-17]].

Aim

This review aims to critically examine the pathophysiological mechanisms underlying

hemostatic dysregulation in anemic children, emphasizing the interplay between impaired oxygen transport and coagulation function.

Methods

This narrative review was conducted to synthesize and critically appraise existing evidence on the relationship between anemia and hemostatic dysregulation in pediatric populations, with particular emphasis on the mechanistic links between impaired oxygen transport and coagulation function. A comprehensive and iterative literature search was performed across major biomedical databases, including PubMed, Scopus, Web of Science, and Google Scholar, covering publications from database inception to the most recent available literature.Search terms were developed using a combination of Medical Subject Headings (MeSH) and free-text keywords related to the core concepts of the review. These included “pediatric anemia,” “childhood anemia,” “hemostasis,” “coagulation,” “platelet function,” “iron deficiency anemia,” “hypoxia,” and “developmental hemostasis.” Boolean operators were applied to refine and expand the search strategy. Reference lists of relevant articles and key reviews were manually screened to identify additional studies not captured in the initial search.

Eligible sources included original research articles, clinical observational studies, mechanistic and translational studies, systematic reviews, and authoritative narrative reviews focusing on children and adolescents. Studies conducted exclusively in adult populations were excluded unless they provided fundamental mechanistic insights directly applicable to pediatric physiology. No restrictions were placed on study design, reflecting the exploratory and integrative nature of a narrative review. Publications in English were prioritized due to accessibility and consistency of interpretation.Data extraction was performed narratively, with emphasis on themes rather than quantitative synthesis. Information was organized around predefined domains, including developmental aspects of pediatric hemostasis, the physiological role of red blood cells in coagulation, platelet abnormalities in anemic states, coagulation pathway alterations, and clinical manifestations of bleeding or thrombosis. Particular attention was given to variations according to anemia etiology, severity, and chronicity.The evidence was interpreted descriptively and contextually, allowing integration of basic science, clinical, and public health perspectives. Given the narrative design, no formal risk-of-bias assessment or meta-analytic techniques were applied. Instead, greater weight was assigned to studies with clear methodology, pediatric relevance, and biological plausibility. This approach enabled a holistic understanding of hemostatic dysregulation in anemic children and identification of knowledge gaps to guide future research.

Pathophysiology of Hemostatic Dysregulation in Anemia

The pathophysiological mechanisms underlying hemostatic dysregulation in anemia are multifactorial and revolve primarily around the effects of impaired oxygen transport on the vascular endothelium, platelet function, and coagulation pathways. Anemia reduces the oxygen-carrying capacity of blood, resulting in tissue hypoxia that triggers compensatory and maladaptive biological responses impacting hemostasis(Table 1) [18-19].

Table 1: Pathophysiology of Hemostatic Dysregulation in Anemia

Pathophysiological Mechanism	Underlying Process	Hemostatic Consequences	Clinical Implications in Children
Reduced hematocrit	Decreased red blood cell mass and blood viscosity	Impaired platelet margination and adhesion	Prolonged bleeding time, mucocutaneous bleeding
Altered blood rheology	Reduced shear stress at vessel wall	Diminished platelet activation	Easy bruising, epistaxis
Increased nitric oxide bioavailability	Reduced hemoglobin-mediated nitric oxide scavenging	Inhibition of platelet aggregation	Functional platelet defects despite normal or high counts
Hypoxia-induced endothelial activation	Upregulation of hypoxia-inducible factors and tissue factor	Enhanced thrombin generation	Risk of thrombosis in chronic or severe anemia
Platelet quantitative changes	Reactive thrombocytosis in iron deficiency	Imbalanced primary hemostasis	Paradoxical bleeding or thrombotic events
Erythrocyte membrane alterations	Phosphatidylserine exposure on damaged red cells	Procoagulant surface for coagulation complexes	Microthrombosis in hemolytic anemias
Inflammatory milieu	Cytokine-mediated endothelial dysfunction	Procoagulant and antifibrinolytic shift	Thromboinflammatory complications
Reduced coagulation factor synthesis	Nutritional deficiency or chronic disease	Impaired secondary hemostasis	Increased bleeding risk during stress or surgery

Endothelial Activation and Dysfunction

Hypoxia induced by anemia plays a central role in endothelial cell activation and dysfunction. Under normal oxygen conditions, the endothelium maintains an anticoagulant surface through the expression of molecules such as thrombomodulin and nitric oxide. However, hypoxia shifts this balance by upregulating procoagulant factors like tissue factor and von Willebrand factor (vWF) and downregulating anticoagulant mediators. This endothelial activation promotes a prothrombotic state, contributing to microvascular occlusions and increased thrombin generation. Furthermore, hypoxia-inducible factors (HIFs) orchestrate gene expression changes in endothelial cells that modulate vascular permeability, inflammation, and coagulation factor production, linking oxygen sensing directly to hemostatic control [20-21].

Platelet Count and Function Alterations

Platelets are highly sensitive to changes in oxygen tension. In anemia-associated hypoxia, platelets may exhibit enhanced reactivity, with increased aggregation and adhesion capacity that favor thrombus formation. This heightened platelet activity is thought to be mediated by increased intracellular calcium signaling and the release of prothrombotic substances such as thromboxane A2. Conversely, some anemic states—particularly those involving bone marrow suppression or nutritional deficiencies—lead to thrombocytopenia or dysfunctional platelets with impaired aggregation responses. The net effect on platelet-mediated primary hemostasis thus depends on the specific anemia etiology and severity, contributing to variability in bleeding or clotting risk among pediatric patients [22-23].

Coagulation Factor Imbalance

Anemia influences the coagulation cascade by altering the levels and activity of coagulation factors. Iron deficiency anemia, one of the most common pediatric forms, has been associated with decreased plasma concentrations of factor VIII and vWF, key components in clot formation and platelet adhesion. This reduction can prolong bleeding time and increase hemorrhagic risk. On

the other hand, chronic hemolytic anemias such as sickle cell disease provoke a hypercoagulable state characterized by elevated tissue factor expression, increased thrombin generation, and impaired fibrinolysis. Inflammatory mediators released during hemolysis exacerbate endothelial dysfunction and coagulation activation. Thus, anemia can simultaneously produce bleeding tendencies and prothrombotic risk depending on the underlying cause and pathophysiology [24-25].

Hemodynamic and Rheological Changes

Anemia induces compensatory hemodynamic responses including increased cardiac output and blood flow velocity to maintain tissue oxygenation. These changes affect shear stress on vessel walls, which in turn influences platelet activation and coagulation factor interactions. Additionally, anemia modifies blood viscosity and red blood cell deformability, which can alter microcirculatory flow and predispose to vascular stasis or turbulence—conditions that favor clot formation. These rheological alterations further complicate the hemostatic landscape in anemic children, particularly in those with coexisting vascular or inflammatory conditions [26].

Interaction Between Hypoxia and Inflammation

Hypoxia in anemia also promotes a pro-inflammatory milieu, which interacts with coagulation pathways in a bidirectional manner. Inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha induce endothelial activation and increase expression of adhesion molecules, facilitating leukocyte and platelet interactions that enhance thrombus formation. Chronic inflammation, common in many anemic states, can suppress natural anticoagulants and impair fibrinolysis, further tipping the balance towards hypercoagulability. This complex interplay underscores the need to consider both hypoxic and inflammatory components when evaluating hemostatic dysfunction in pediatric anemia [27].

Clinical Implications

Hemostatic dysregulation in anemic children carries significant clinical consequences, as it predisposes this vulnerable population to a complex spectrum of bleeding and thrombotic complications. Recognizing these risks is essential for clinicians to optimize management strategies and improve pediatric outcomes [28].Children with anemia face a paradoxical hemostatic state where both hemorrhagic and thrombotic events can occur depending on the underlying anemia type, severity, and concurrent conditions. For example, iron deficiency anemia, the most widespread form globally, is often associated with mild coagulation factor deficiencies, such as reduced von Willebrand factor and factor VIII levels, which can manifest clinically as mucocutaneous bleeding, prolonged bleeding times, and increased bleeding during surgical interventions or trauma. Such bleeding risks can complicate routine procedures like venipuncture or minor surgeries, necessitating careful hemostatic assessment prior to intervention [29].

Conversely, chronic hemolytic anemias—most notably sickle cell disease—present a hypercoagulable milieu characterized by endothelial activation, platelet hyperreactivity, and increased thrombin generation. This prothrombotic tendency contributes to serious complications such as vaso-occlusive crises, stroke, and pulmonary embolism, which significantly impact morbidity and mortality. Children with sickle cell anemia thus require vigilant monitoring for thrombotic events and may benefit from prophylactic anticoagulation or antiplatelet therapies, although these interventions carry their own bleeding risks and must be judiciously applied [30-31].Additionally, anemia-induced hemostatic dysfunction complicates clinical management by influencing transfusion strategies. Blood transfusions aimed at correcting anemia may inadvertently exacerbate hypercoagulability or provoke immune-mediated reactions affecting coagulation. Hence, transfusion thresholds and protocols must be individualized, balancing the need to improve oxygen delivery against the potential for

promoting thrombosis [32-33].The co-existence of anemia and other comorbidities such as infections, malnutrition, or chronic inflammation further amplifies hemostatic abnormalities, complicating diagnosis and treatment. In resource-limited settings, where anemia prevalence is high and access to advanced coagulation testing is limited, these challenges are even more pronounced, highlighting the need for simple, reliable clinical tools to assess bleeding and clotting risk [34-35].

Diagnostic Considerations

Accurate diagnosis of hemostatic dysregulation in anemic children is essential but often challenging due to the complex interplay between oxygen transport deficits and coagulation abnormalities. Traditional coagulation tests, while useful, may not fully capture the nuanced hemostatic changes associated with various forms of anemia, necessitating a more integrative and sophisticated diagnostic approach [36].Standard laboratory assessments such as complete blood count (CBC) provide foundational information on hemoglobin levels, red blood cell indices, and platelet counts, which are critical in identifying anemia type and severity. However, platelet quantity alone may not reflect functional abnormalities that contribute to bleeding or thrombosis risk. Therefore, platelet function assays—including platelet aggregation studies and flow cytometry for activation markers—can offer valuable insight into qualitative platelet defects commonly observed in anemic states, especially those related to hypoxia-induced platelet hyperreactivity or dysfunction [37].

Routine coagulation profiles including prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen levels serve as initial screening tools to detect gross abnormalities in coagulation pathways. Yet, these tests may not reveal subtle imbalances or hypercoagulable states frequently present in chronic anemia. Measurement of specific coagulation factors, such as von Willebrand factor and factor VIII, is particularly important in iron deficiency anemia, where deficiencies contribute to bleeding risk. Additionally, assays evaluating natural anticoagulants like protein C, protein S, and antithrombin III may help identify acquired deficiencies that exacerbate thrombotic predisposition [38].Advanced global hemostasis assessments such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM) provide dynamic real-time evaluation of clot formation, stability, and fibrinolysis, offering a more comprehensive picture of hemostatic function. These modalities have shown promise in detecting both hypo- and hypercoagulable states in anemic children and may guide individualized management decisions, particularly in perioperative settings or severe anemia [39].Assessment of oxygenation status—including pulse oximetry and arterial blood gas analysis—should be integrated with hemostatic testing to contextualize coagulation abnormalities within the severity of hypoxia. Additionally, biomarkers of endothelial activation (e.g., soluble thrombomodulin, E-selectin) and inflammation (e.g., C-reactive protein, interleukins) can further elucidate the pathophysiological mechanisms driving coagulation disturbances and assist in risk stratification [40].

Therapeutic Approaches

Management of hemostatic dysregulation in anemic children requires a comprehensive approach targeting both the underlying anemia and the associated coagulation abnormalities. Treatment strategies must be individualized, considering the anemia etiology, severity, and the patient's bleeding or thrombotic risk profile, to optimize outcomes while minimizing complications [41].

Correction of Anemia

The cornerstone of therapy is correction of the anemia to restore adequate oxygen delivery, which can indirectly ameliorate hemostatic disturbances. Nutritional supplementation with iron, folate, or vitamin B12 remains the primary intervention for deficiency anemias. Oral iron therapy is generally preferred for mild to moderate iron deficiency anemia, while intravenous formulations may be indicated in cases of malabsorption or severe anemia.

Hemoglobinopathies, such as sickle cell disease, often require more complex management including hydroxyurea therapy, chronic transfusions, or bone marrow transplantation to reduce hemolysis and improve red blood cell function [42-43].Blood transfusions can rapidly correct severe anemia and improve oxygenation; however, they must be judiciously administered as they carry risks of alloimmunization, iron overload, and paradoxically, exacerbation of hypercoagulability. Transfusion thresholds should be carefully considered, particularly in children with underlying thrombotic predispositions [44].

Management of Coagulation Abnormalities

Therapeutic interventions targeting hemostatic dysfunction depend on whether bleeding or thrombotic tendencies predominate. For bleeding risk associated with coagulation factor deficiencies or platelet dysfunction, supportive measures include administration of clotting factor concentrates, desmopressin (which can elevate von Willebrand factor and factor VIII), or platelet transfusions as clinically indicated. Nutritional rehabilitation to correct deficiencies can also improve platelet and coagulation factor function [45].In cases where hypercoagulability prevails, as commonly seen in hemolytic anemias like sickle cell disease, prophylactic or therapeutic anticoagulation may be warranted. Low-dose aspirin is frequently employed to reduce platelet aggregation and prevent vaso-occlusive events, while low molecular weight heparin or direct oral anticoagulants may be considered for thrombotic complications. The risk-benefit ratio of anticoagulant therapy must be carefully balanced against potential bleeding risks, particularly in pediatric patients [46].

Adjunctive and Supportive Therapies

Addressing underlying inflammation and endothelial dysfunction is an emerging therapeutic strategy. Anti-inflammatory agents and antioxidants may help mitigate endothelial activation and reduce prothrombotic stimuli, though clinical evidence in pediatric anemia is limited. Emerging molecular therapies targeting hypoxia-inducible pathways and coagulation signaling offer potential for more precise modulation of hemostatic balance [47-48].

Monitoring and Multidisciplinary Care

Regular monitoring of hemoglobin levels, coagulation parameters, and clinical status is essential to guide therapy adjustments and prevent complications. Multidisciplinary collaboration involving pediatric hematologists, cardiologists, and coagulation specialists enhances comprehensive care, particularly for children with complex anemia syndromes [48].

Conclusion

Hemostatic dysregulation in anemic children represents a complex and clinically significant interplay between impaired oxygen transport and coagulation abnormalities. The diverse mechanisms triggered by anemia-induced hypoxia—including endothelial dysfunction, platelet alterations, and coagulation factor imbalances—create a dynamic hemostatic environment that predisposes to both bleeding and thrombotic complications. Recognizing these interactions is critical for accurate diagnosis, risk stratification, and individualized management in pediatric patients. Integration of advanced diagnostic tools and comprehensive clinical assessment is necessary to optimize therapeutic strategies that address both anemia correction and coagulation stabilization.

Abbreviations

ADP – Adenosine Diphosphate
DIC – Disseminated Intravascular Coagulation
ET – Endothelial Tissue
Hb – Hemoglobin
Hct – Hematocrit
HIF – Hypoxia-Inducible Factor
IDA – Iron Deficiency Anemia
IL – Interleukin
NO – Nitric Oxide
PS – Phosphatidylserine
RBC – Red Blood Cell
TF – Tissue Factor
vWF – von Willebrand Factor

References

1. Hess SY, Owais A, Jefferds MED, Young MF, Cahill A, Rogers LM. Accelerating action to reduce anemia: Review of causes and risk factors and related data needs. Ann N Y Acad Sci. 2023;1523(1):11-23. doi: 10.1111/nyas.14985.
2. Scott SP, Chen-Edinboro LP, Caulfield LE, Murray-Kolb LE. The Impact of Anemia on Child Mortality: An Updated Review. Nutrients. 2014; 6(12):5915-5932. https://doi.org/10.3390/nu6125915
3. Martinez-Torres V, Torres N, Davis JA, Corrales-Medina FF. Anemia and Associated Risk Factors in Pediatric Patients. Pediatric Health Med Ther. 2023; 14:267-280. doi: 10.2147/PHMT.S389105.
4. Parodi E, Riboldi L, Ramenghi U. Hemoglobin life-threatening value (1.9 g/dl) in good general condition: a pediatric case-report. Ital J Pediatr. 2021;47(1):200. doi: 10.1186/s13052-021-01146-w.
5. Pierce A, Pittet JF. Practical understanding of hemostasis and approach to the bleeding patient in the OR. Adv Anesth. 2014;32(1):1-21. doi: 10.1016/j.aan.2014.08.009.
6. Scridon A. Platelets and Their Role in Hemostasis and Thrombosis—From Physiology to Pathophysiology and Therapeutic Implications. International Journal of Molecular Sciences. 2022; 23(21):12772. https://doi.org/10.3390/ijms232112772
7. Janaszak-Jasiecka A, Siekierzycka A, Płoska A, Dobrucki IT, Kalinowski L. Endothelial Dysfunction Driven by Hypoxia-The Influence of Oxygen Deficiency on NO Bioavailability. Biomolecules. 2021;11(7):982. doi: 10.3390/biom11070982.
8. Xu Y, Yu Z, Liu H, Bian X, Tang W. Erythrocytes enhance oxygen-carrying capacity through self-regulation. Front Physiol. 2025; 16:1592176. doi: 10.3389/fphys.2025.1592176.
9. Scridon A. Platelets and Their Role in Hemostasis and Thrombosis-From Physiology to Pathophysiology and Therapeutic Implications. Int J Mol Sci. 2022;23(21):12772. doi: 10.3390/ijms232112772.
10. Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res. 2013;112(11):1506-19. doi: 10.1161/CIRCRESAHA.113.300512.
11. Kalff H, Cario H, Holzhauer S. Iron deficiency anemia and thrombosis risk in children-revisiting an old hypothesis. Front Pediatr. 2022; 10:926925. doi: 10.3389/fped.2022.926925.
12. van Ommen CH, Peters M. The bleeding child. Part I: primary hemostatic disorders. Eur J Pediatr. 2012;171(1):1-10. doi: 10.1007/s00431-011-1532-4.
13. Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 2016;30(4):245-256. doi: 10.1016/j.blre.2015.12.003.
14. Tuono RM, Simo JL, Njopwouo MS, Tayou CT. Abnormalities of hemostasis in sickle cell patients and predisposition to thrombotic risk: a systematic review and meta-analysis. Thromb J. 2025;23(1):110. doi: 10.1186/s12959-025-00804-x.
15. Obeagu EI, Olateju OR. Integrating sickle cell disease care into primary healthcare in Uganda: a narrative review. Ann Med Surg (Lond). 2025;87(9):5918-5924. doi: 10.1097/MS9.0000000000003713.
16. Obeagu EI. Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review. Ann Med Surg (Lond). 2025;87(6):3279-3288. doi: 10.1097/MS9.0000000000002981.

17. Obeagu EI, Obeagu GU. Anemia and cerebrovascular disease: pathophysiological insights and clinical implications. Ann Med Surg (Lond). 2025;87(6):3254-3267. doi: 10.1097/MS9.0000000000002907.
18. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000;15 Suppl 3:14-8. doi: 10.1093/oxfordjournals.ndt.a027970.
19. Janaszak-Jasiecka A, Siekierzycka A, Płoska A, Dobrucki IT, Kalinowski L. Endothelial Dysfunction Driven by Hypoxia-The Influence of Oxygen Deficiency on NO Bioavailability. Biomolecules. 2021;11(7):982. doi: 10.3390/biom11070982.
20. Chennupati R, Solga I, Wischmann P, Dahlmann P, Celik FG, Pacht D, Şahin A, Yogathasan V, Hosen MR, Gerdes N, Kelm M, Jung C. Chronic anemia is associated with systemic endothelial dysfunction. Front Cardiovasc Med. 2023; 10:1099069. doi: 10.3389/fcvm.2023.1099069.
21. Tian Y, Zong Y, Pang Y, Zheng Z, Ma Y, Zhang C, Gao J. Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduct Target Ther. 2025;10(1):159. doi: 10.1038/s41392-025-02198-8.
22. Periayah MH, Halim AS, Mat Saad AZ. Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis. Int J Hematol Oncol Stem Cell Res. 2017;11(4):319-327.
23. Kalff H, Cario H, Holzhauer S. Iron deficiency anemia and thrombosis risk in children-revisiting an old hypothesis. Front Pediatr. 2022; 10:926925. doi: 10.3389/fped.2022.926925.
24. van Ommen CH, Peters M. The bleeding child. Part I: primary hemostatic disorders. Eur J Pediatr. 2012;171(1):1-10. doi: 10.1007/s00431-011-1532-4.
25. Quante M, Pulzer F, Bläser A, Gebauer C, Kluge J, Robel-Tillig E. Effects of anaemia on haemodynamic and clinical parameters in apparently stable preterm infants. Blood Transfus. 2013;11(2):227-232. doi: 10.2450/2012.0171-11.
26. Obeagu EI. Hypoxia, Inflammation, and Cytokine Crosstalk in Sickle Cell Disease: From Mechanisms to Modulation- A Narrative Review. Pediatric Health Med Ther. 2025; 16:217-225. doi: 10.2147/PHMT.S544217.
27. O'Brien SH, Zia A. Hemostatic and thrombotic disorders in the pediatric patient. Blood. 2022;140(6):533-541. doi: 10.1182/blood.2020006477.
28. Obeagu EI, Obeagu GU. Anemia and cerebrovascular disease: pathophysiological insights and clinical implications. Ann Med Surg (Lond). 2025;87(6):3254-3267. doi: 10.1097/MS9.0000000000002907.
29. Gladwin MT, Kato GJ. Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens! Haematologica. 2008;93(1):1-3. doi: 10.3324/haematol.12318.
30. Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 2016;30(4):245-256. doi: 10.1016/j.blre.2015.12.003.
31. Kiyatkin ME, Mladinov D, Jarzebowski ML, Warner MA. Patient Blood Management, Anemia, and Transfusion Optimization Across Surgical Specialties. Anesthesiol Clin. 2023;41(1):161-174. doi: 10.1016/j.anclin.2022.10.003.
32. Li L, Yang J, Sun Y, Dang Q, Xu C, Chen P, Ma T, Ren J. Correction of blood coagulation dysfunction and anemia by supplementation of red blood cell suspension, fresh frozen plasma, and apheresis platelet: results of in vitro hemodilution experiments. J Crit Care. 2015;30(1): 220.e1-12. doi: 10.1016/j.jcrc.2014.09.019.

33. Mohamed AA. Prevalence and Comorbidities of Anemia in Hospitalized Adults. Cureus. 2025;17(2): e79568. doi: 10.7759/cureus.79568.
34. Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Ann N Y Acad Sci. 2019;1450(1):15-31. doi: 10.1111/nyas.14092.
35. van Ommen CH, Peters M. The bleeding child. Part I: primary hemostatic disorders. Eur J Pediatr. 2012;171(1):1-10. doi: 10.1007/s00431-011-1532-4.
36. Seo IH, Lee YJ. Usefulness of Complete Blood Count (CBC) to Assess Cardiovascular and Metabolic Diseases in Clinical Settings: A Comprehensive Literature Review. Biomedicines. 2022;10(11):2697. doi: 10.3390/biomedicines10112697.
37. Mohammadi Aria M, Erten A, Yalcin O. Technology Advancements in Blood Coagulation Measurements for Point-of-Care Diagnostic Testing. Front BioengBiotechnol. 2019; 7:395. doi: 10.3389/fbioe.2019.00395.
38. Akay OM. The Double Hazard of Bleeding and Thrombosis in Hemostasis from a Clinical Point of View: A Global Assessment by Rotational Thromboelastometry (ROTEM). Clin Appl ThrombHemost. 2018;24(6):850-858. doi: 10.1177/1076029618772336.
39. Gao J, Zhang Z, Yan JY, Ge YX, Gao Y. Inflammation and coagulation abnormalities via the activation of the HMGB1-RAGE/NF-κB and F2/Rho pathways in lung injury induced by acute hypoxia. Int J Mol Med. 2023;52(2):67. doi: 10.3892/ijmm.2023.5270.
40. Gallagher PG. Anemia in the pediatric patient. Blood. 2022;140(6):571-593. doi: 10.1182/blood.2020006479.
41. Remacha AF, Wright I, Fernández-Jiménez MC, Toxqui L, Blanco-Rojo R, Moreno G, Vaquero MP. Vitamin B12 and folate levels increase during treatment of iron deficiency anaemia in young adult woman. Int J Lab Hematol. 2015;37(5):641-648. doi: 10.1111/ijlh.12378.
42. Pantopoulos K. Oral iron supplementation: new formulations, old questions. Haematologica. 2024;109(9):2790-2801. doi: 10.3324/haematol.2024.284967.
43. İnce C. Blood Transfusions Correct Anemia and Improve Tissue Oxygenation in Surgical and Critically ill Patients. Turk J AnaesthesiolReanim. 2017;45(3):119-121. doi: 10.5152/TJAR.2017.08051.
44. Mohinani A, Patel S, Tan V, Kartika T, Olson S, DeLoughery TG, Shatzel J. Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. Eur J Haematol. 2023;110(5):470-479. doi: 10.1111/ejh.13930.
45. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica. 2009;94(11):1481-1484. doi: 10.3324/haematol.2009.013672.
46. Radenković M, Stojanović M, Potpara T, Prostran M. Therapeutic approach in the improvement of endothelial dysfunction: the current state of the art. Biomed Res Int. 2013;2013:252158. doi: 10.1155/2013/252158.
47. Darwish I, Liles WC. Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction. Virulence. 2013;4(6):572-582. doi: 10.4161/viru.25740.

48. OkurAcar S, TüfekçiGürocak Ö. Patient Blood Management in Pediatric Patients: Current Strategies and Future Perspectives. Turk J Haematol. 2025;42(3):170-180. doi: 10.4274/tjh.galenos.2025.2025.0301.

Access this Article in Online	
Quick Response Code	Website: www.ijcrims.com
	Subject: Haematology
DOI: 10.22192/ijcrms.2026.12.03.004	

How to cite this article:
Emmanuel Ifeanyi Obeagu and Ohiwerei Wisdom Omogbai. (2026). Hemostatic Dysregulation in Anemic Children: Bridging the Gap Between Oxygen Transport and Coagulation Function. Int. J. Curr. Res. Med. Sci. 12(3): 32-42.
DOI: http://dx.doi.org/10.22192/ijcrms.2026.12.03.004